Detalles de la búsqueda
1.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol;
102(10): 2741-2752, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592092
2.
Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial.
Diabetologia;
64(5): 1079-1092, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33515070
3.
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Am J Hematol;
94(11): 1236-1243, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31456269
4.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Lancet Oncol;
19(6): 747-757, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29735299
5.
Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
Cancer;
123(13): 2467-2471, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28192602
6.
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Blood;
126(1): 42-9, 2015 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-25918346
7.
The impact of health care settings on survival time of patients with chronic myeloid leukemia.
Blood;
123(16): 2494-6, 2014 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24622328
8.
Comprehensive mutational profiling in advanced systemic mastocytosis.
Blood;
122(14): 2460-6, 2013 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23958953
9.
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.
Ann Hematol;
94 Suppl 2: S209-18, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25814087
10.
A multi-state model approach for prediction in chronic myeloid leukaemia.
Ann Hematol;
94(6): 919-27, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25465231
11.
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Ann Hematol;
94(12): 2015-24, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26385387
12.
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Haematologica;
99(9): 1441-7, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24837466
13.
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Ann Hematol;
93(1): 71-80, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24162333
14.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
J Clin Oncol;
: JCO2301647, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38471049
15.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia;
38(5): 1072-1080, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38548962
16.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia;
38(2): 318-325, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129513
17.
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Blood;
118(3): 686-92, 2011 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-21536864
18.
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Blood;
118(26): 6760-8, 2011 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22039253
19.
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Haematologica;
98(5): 714-7, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23065514
20.
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
Lancet Oncol;
13(2): 207-14, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197676